You are using onelink.to to download an app.Unfortunately there is no download link for your device.It seems like you are using a non-mobile device.The application is available foriPhone, iPad, and iPodAndroidAre you the owner of this onelink.to link?Instead of showing this page when someone uses your onelink.to link from a device without download link, add a fallback URL. Then we will send all…
Pediatric Hospital Medicine: A High-Value Approach
Radial arterial catheters (RAC) are used extensively across critical care settings (Anesthesia, Intensive Care, Emergency Medicine) for continuous hemodynamic m…
ROHHAD is an acronym for rapid-onset obesity (RO) with hypothalamic dysregulation (H), hypoventilation (H), and autonomic dysregulation (AD). It is a rare, life-threatening syndrome that…
Efgartigimod significantly increased sustained platelet count responses compared with placebo in patients with chronic immune thrombocytopenia, including those who had received multiple previous immune thrombocytopenia…
Valvular heart disease (VHD) is becoming more prevalent in an ageing population, leading to challenges in diagnosis and management. This two-part Series offers a comprehensive…
Valvular heart disease is common and its prevalence is rapidly increasing worldwide. Effective medical therapies are insufficient and treatment was historically limited to the surgical…
I.M. Matters from ACP provides news and information for internal medicine physicians about the practice of medicine and reports on the policies, products, and activities…
Half of emergency department (ED) patients aged 65 years and older are discharged with new prescriptions. Potentially inappropriate prescriptions contribute to adverse drug events. Our…
Discover the first oral therapy designed to prevent hereditary angioedema attacks. Find treatment info & see how ORLADEYO® is different.
In adults with overweight and obesity, phentermine–topiramate and GLP-1 receptor agonists proved the best drugs in reducing weight; of the GLP-1 agonists, semaglutide might be…
